BioNTech
BNTX
303 hedge funds and large institutions have $5.79B invested in BioNTech in 2024 Q4 according to their latest regulatory filings, with 63 funds opening new positions, 84 increasing their positions, 88 reducing their positions, and 49 closing their positions.
39% more call options, than puts
Call options by funds: $373M | Put options by funds: $269M
29% more first-time investments, than exits
New positions opened: 63 | Existing positions closed: 49
10% more capital invested
Capital invested by funds: $5.24B → $5.79B (+$546M)
2.75% more ownership
Funds ownership: 18.6% → 21.35% (+2.7%)
2% more funds holding
Funds holding: 296 → 303 (+7)
0% more funds holding in top 10
Funds holding in top 10: 7 → 7 (0)
5% less repeat investments, than reductions
Existing positions increased: 84 | Existing positions reduced: 88
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$160M |
| 2 |
Viking Global Investors
Stamford,
Connecticut
|
+$102M |
| 3 |
BNP Paribas Financial Markets
Paris,
France
|
+$70.1M |
| 4 |
DZ Bank
Frankfurt Am Main,
Germany
|
+$49.5M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$46.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
-$73.7M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$43M |
| 3 |
CII
Capital International Inc
Los Angeles,
California
|
-$29.9M |
| 4 |
Primecap Management
Pasadena,
California
|
-$25.2M |
| 5 |
BlackRock
New York
|
-$24.6M |
BNTX Hedge Fund Activity: Q4 2024 in Review
303 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in BioNTech (BNTX) for Q4 2024, worth a combined $5.79B — up 10% from $5.24B a quarter earlier.
Buyers outnumbered sellers: 63 funds opened new BNTX positions and 49 closed out — a net gain of 14 holders — while 84 added to existing stakes and 88 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $160M. The largest seller was Balyasny Asset Management, exiting entirely with an estimated $73.7M sold.
- 303 institutional investors held BioNTech (BNTX) as of Q4 2024, up from 296 in Q3 2024.
- Funds reported $5.79B of BioNTech stock for Q4 2024, up 10% quarter-over-quarter.
- 63 funds opened new BioNTech positions in Q4 2024 and 49 closed out, a net change of +14 holders.
- The largest BioNTech buyer in Q4 2024 was Fidelity Investments, an estimated $160M added.
- The largest BioNTech seller in Q4 2024 was Balyasny Asset Management, an estimated $73.7M sold.
Based on aggregated 13F filings for Q4 2024.